Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?

Bluebird and Celgene are focused on moving bb2121 into earlier lines of multiple myeloma therapy. Positive early data was was the opening headliner at ASCO, showing PFS improvements of about a year in heavily pre-treated patients – meeting expectations, though not overwhelming.